化療
摘要號：GS2-02
Efficacy and utilization trends of adjuvant chemotherapy for stage I, II, and III breast cancer in the elderly population: A National Cancer Database (NCDB) analysis
老年人群Ⅰ至Ⅲ期乳腺癌輔助化療的療效和應(yīng)用趨勢：國家癌癥數(shù)據(jù)庫（NCDB）
摘要號：GS2-03
Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients
新輔助化療后pCR及對乳腺癌復(fù)發(fā)和死亡的影響，按乳腺癌亞型和輔助化療分層：一項27,000余人的個體患者水平薈萃分析
摘要號：GS2-04
Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer
CIBOMA / 2004-01_GEICAM / 2003-11研究：一項隨機(jī)Ⅲ期臨床試驗評估早期TNBC標(biāo)準(zhǔn)化療后輔助卡培他濱治療效果
內(nèi)分泌治療
摘要號：GS3-01
A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ
一項隨機(jī)Ⅲ期研究：低劑量TAM用于預(yù)防激素敏感性乳腺導(dǎo)管或小葉原位癌復(fù)發(fā)
摘要號：GS3-02
PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib
PALLET：一項比較letrozole單藥或聯(lián)合palbociclib新輔助治療的臨床效果和抗增殖作用的研究
摘要號：GS3-03
Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women
延長AI輔助治療超過5年對復(fù)發(fā)和病因特異性死亡率的影響：EBCTCG一項納入12項隨機(jī)試驗、24912名婦女個體患者數(shù)據(jù)的薈萃分析
摘要號：GS3-04
A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years - Results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS)
將芳香化酶抑制劑輔助治療延長至10年的前瞻性隨機(jī)多中心開放標(biāo)簽Ⅲ期試驗——來自1697名絕經(jīng)后婦女的N-SAS BC 05試驗結(jié)果：Arimidex延長輔助隨機(jī)研究（AERAS）
摘要號：GS4-07
Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial
HR陽性、HER2陰性、淋巴結(jié)陰性乳腺癌的人種、種族和臨床結(jié)果：TAILORx試驗結(jié)果
摘要號：GS6-03
Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results
內(nèi)分泌治療和與內(nèi)分泌聯(lián)合化療的癥狀及健康相關(guān)生存質(zhì)量的對比：TAILORx試驗的患者報告
乳腺癌風(fēng)險預(yù)測
摘要號：GS3-06
Dynamics of breast cancer relapse reveal molecularly defined late recurring ER-positive subgroups: Results from the METABRIC study
乳腺癌復(fù)發(fā)動力學(xué)揭示晚期復(fù)發(fā)ER陽性亞群：來自代謝研究的結(jié)果
摘要號：GS3-07
Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+HER2-metastatic breast cancer: Results of the phase III STIC CTC trial
循環(huán)腫瘤細(xì)胞計數(shù)作為ER+/HER2-轉(zhuǎn)移性乳腺癌一線激素治療和化療選擇的工具：Ⅲ期STIC CTC試驗結(jié)果
摘要號：GS2-01
Age-related breast cancer risk estimates for the general population based on sequencing of cancer predisposition genes in 19,228 breast cancer patients and 20,211 matched unaffected controls from US based cohorts in the CARRIERS study
CARRIERS研究：基于來自美國隊列的19,228名乳腺癌患者和20,211名未受影響的對照者中,一般人群的癌癥易感基因測序的年齡相關(guān)乳腺癌風(fēng)險估計值
靶向治療
摘要號：GS3-08
Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial
Alpelisib +氟維司群用于晚期乳腺癌: 來自Ⅲ期SOLAR-1試驗的亞組分析
摘要號：GS2-07
PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer
PHARE隨機(jī)試驗最終結(jié)果：對比早期乳腺癌6和12個月曲妥珠單抗治療效果
摘要號：P6-17-17
Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY)
帕妥珠單抗+曲妥珠單抗聯(lián)合多西他賽新輔助治療早期或局部晚期HER-2+亞洲乳腺癌患者的療效和安全性分析的隨機(jī)對照3期臨床研究（PEONY）
摘要號：GS1-10
Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE
KATHERINE研究：新輔助治療后仍有殘存病灶早期HER2+乳腺癌患者，T-DM1對比曲妥珠單抗輔助治療的Ⅲ期研究結(jié)果
免疫治療
摘要號：GS1-04
IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-na?ve, locally advanced or metastatic triple-negative breast cancer
IMpassion130：來自治療初治、局部晚期或轉(zhuǎn)移性三陰性乳腺癌患者的atezolizumab +白蛋白紫杉醇的全球、隨機(jī)、雙盲、安慰劑對照、Ⅲ期研究的免疫生物標(biāo)志物亞組的功效
摘要號：PD3-01
Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
KATE2研究結(jié)果：atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1在晚期HER2+乳腺癌的隨機(jī)2期臨床研究
外科
摘要號：GS6-01
Surgical treatment after neoadjuvant systemic therapy in young women with breast cancer: Results from a prospective cohort study
一項年輕女性乳腺癌新輔助全身治療后手術(shù)治療的前瞻性隊列研究結(jié)果
摘要號：GS-05
The impact of breast cancer surgery on quality of life: Long term results from E5103
乳腺癌手術(shù)對生活質(zhì)量的影響：E5103的長期結(jié)果
摘要號：GS6-06
Local therapy and quality of life outcomes in young women with breast cancer
乳腺癌年輕女性的局部治療和生活質(zhì)量結(jié)果
12月4日-8日，《腫瘤瞭望》與您共赴乳腺癌“阿拉莫之戰(zhàn)”——2018年圣安東尼奧乳腺癌研討會
（來源：《腫瘤瞭望》編輯部）
